Skip to content

Polatuzumab vedotin

Polivy (polatuzumab vedotin) is an antibody pharmaceutical. Polatuzumab vedotin was first approved as Polivy on 2019-06-10. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat b-cell lymphoma. The pharmaceutical is active against B-cell antigen receptor complex-associated protein beta chain.
Trade Name Polivy
Common Name Polatuzumab vedotin
Indication b-cell lymphoma, large b-cell lymphoma diffuse
Drug Class Synthetic analogs of the dolastatin series; monoclonal antibodies: humanized, tumors as target
Polatuzumab vedotin
Get full access now